Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate plus betamethasone eye drops for idiopathic scleritis
jRCTs051230023Recruiting
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of methotrexate and betamethasone in scleritis. Primary endpoint: Treatment success at 24 weeks. Started Aug 2023; status: recruiting.
02
Drugs
methotrexatebetamethasone
03
Conditions
scleritis
Beyond the preview
Go deeper on jRCTs051230023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230023.